Peritoneal carcinomatosis with intraperitoneal immunotherapy: current treatment options and perspectives

References

• Ahmed N, Stenvers KL. Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. Front Oncol. 2013;3:256. DOI:10.3389/fonc.2013.00256.
   PubMedGoogle Scholar
• Ströhlein MA, Heiss MM, Jauch KW. The current status of immunotherapy in peritoneal carcinomatosis. Expert Rev Anticancer Ther. 2016;16(10):1019–1027.
   PubMed Web of Science ®Google Scholar
• Ayantunde AA, Parsons SL. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol. 2007;18(5):945–949.
   PubMed Web of Science ®Google Scholar
• Ceelen W, Ramsay RG, Narasimhan V, et al., Targeting the tumor microenvironment in colorectal peritoneal metastases. Trends Cancer. 6(3): 236–246. 2020.
   PubMed Web of Science ®Google Scholar
• Hong H, Brown CE, Ostberg JR, et al. L1 cell adhesion molecule-specific chimeric antigen receptor-redirected human t cells exhibit specific and efficient antitumor activity against human ovarian cancer in mice. PloS One. 2016;11(1):e0146885.
   PubMed Web of Science ®Google Scholar
• Grekova SP, Aprahamian M, Daeffler L, et al. Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer. Cancer Biol Ther. 2011;12(10):888–895.
   PubMed Web of Science ®Google Scholar
• Xiao L, Cen D, Gan H, et al. Adoptive Transfer of NKG2D CAR mRNA-engineered natural killer cells in colorectal cancer patients. Mol Ther. 2019;27(6):1114–1125.
   PubMed Web of Science ®Google Scholar
• Wada I, Matsushita H, Noji S, et al. Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer. Cancer Med. 2014;3(2):362–375.
   PubMed Web of Science ®Google Scholar
• Ceelen W, Braet H, van Ramshorst G, et al. Intraperitoneal chemotherapy for peritoneal metastases: an expert opinion. Expert Opin Drug Deliv. 2020;17(4):511–522.
   PubMed Web of Science ®Google Scholar
• Pretzsch E, Bösch F, Neumann J, et al. Mechanisms of metastasis in colorectal cancer and metastatic organotropism: hematogenous versus peritoneal spread. J Oncol. 2019;2019:7407190.
   PubMed Web of Science ®Google Scholar
• Lessan K, Aguiar DJ, Oegema T, et al. CD44 and beta1 integrin mediate ovarian carcinoma cell adhesion to peritoneal mesothelial cells. Am J Pathol. 1999;154(5):1525–1537.
   PubMed Web of Science ®Google Scholar
• Iwanicki MP, Davidowitz RA, Ng MR, et al. Ovarian cancer spheroids use myosin-generated force to clear the mesothelium. Cancer Discov. 2011;1(2):144–157.
   PubMed Web of Science ®Google Scholar
• Mikuła-Pietrasik J, Uruski P, Matuszkiewicz K, et al. Ovarian cancer-derived ascitic fluids induce a senescence-dependent pro-cancerogenic phenotype in normal peritoneal mesothelial cells. Cell Oncol (Dordr). 2016;39(5):473–481.
   PubMed Web of Science ®Google Scholar
• Kaji M, Yonemura Y, Harada S, et al. Participation of c-met in the progression of human gastric cancers: anti-c-met oligonucleotides inhibit proliferation or invasiveness of gastric cancer cells. Cancer Gene Ther. 1996;3(6):393–404.
   PubMed Web of Science ®Google Scholar
• Mikuła-Pietrasik J, Uruski P, Tykarski A, et al., The peritoneal “soil” for a cancerous “seed”: a comprehensive review of the pathogenesis of intraperitoneal cancer metastases. Cell Mol Life Sci. 75(3): 509–525. 2018.
   PubMed Web of Science ®Google Scholar
• Riabov V, Gudima A, Wang N, et al. Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. Front Physiol. 2014;5:75.
   PubMed Web of Science ®Google Scholar
• Duluc D, Delneste Y, Tan F, et al. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood. 2007;110(13):4319–4330.
   PubMed Web of Science ®Google Scholar
• Chow A, Schad S, Green MD, et al. Tim-4(+) cavity-resident macrophages impair anti-tumor CD8(+) T cell immunity. Cancer Cell. 2021;39(7):973–88.e9.
   PubMed Web of Science ®Google Scholar
• Xiang F, Wu K, Liu Y, et al. Omental adipocytes enhance the invasiveness of gastric cancer cells by oleic acid-induced activation of the PI3K-Akt signaling pathway. Int J Biochem Cell Biol. 2017;84:14–21.
   PubMed Web of Science ®Google Scholar
• Glehen O, Mohamed F, Gilly FN. Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol. 2004;5(4):219–228.
   PubMed Web of Science ®Google Scholar
• Steis RG, Urba WJ, VanderMolen LA, et al. Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity. J Clin Oncol. 1990;8(10):1618–1629.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Yang H, Kim WR, et al. STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer. J Immunother Cancer. 2021;9(6):e002195.
   PubMed Web of Science ®Google Scholar
• Modak S, Zanzonico P, Grkovski M, et al. B7H3-directed intraperitoneal radioimmunotherapy with radioiodinated omburtamab for desmoplastic small round cell tumor and other peritoneal tumors: results of a phase I study. J Clin Oncol. 2020;38(36):4283–4291.
   PubMed Web of Science ®Google Scholar
• Palm S, Bäck T, Aneheim E, et al. Evaluation of therapeutic efficacy of (211) at-labeled farletuzumab in an intraperitoneal mouse model of disseminated ovarian cancer. Transl Oncol. 2021;14(1):100873.
   PubMed Web of Science ®Google Scholar
• Li HK, Morokoshi Y, Nagatsu K, et al. Locoregional therapy with α-emitting trastuzumab against peritoneal metastasis of human epidermal growth factor receptor 2-positive gastric cancer in mice. Cancer Sci. 2017;108(8):1648–1656.
   PubMed Web of Science ®Google Scholar
• Heiss MM, Murawa P, Koralewski P, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer. 2010;127(9):2209–2221.
   PubMed Web of Science ®Google Scholar
• Chon HJ, Lee WS, Yang H, et al. Tumor microenvironment remodeling by intratumoral oncolytic vaccinia virus enhances the efficacy of immune-checkpoint blockade. Clin Cancer Res off J Am Assoc Cancer Res. 2019;25(5):1612–1623.
   PubMed Web of Science ®Google Scholar
• Lee YS, Lee WS, Kim CW, et al. Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer. J Immunother Cancer. 2020;8(2):e000857.
   PubMed Web of Science ®Google Scholar
• Chekmasova AA, Rao TD, Nikhamin Y, et al. Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. Clin Cancer Res off J Am Assoc Cancer Res. 2010;16(14):3594–3606.
   PubMed Web of Science ®Google Scholar
• Yoo SY, Badrinath N, Jeong SN, et al. Overcoming tumor resistance to oncolyticvaccinia virus with Anti-PD-1-based combination therapy by inducing antitumor immunity in the tumor microenvironment. Vaccines (Basel). 2020;8(2):321.
   PubMed Web of Science ®Google Scholar
• Muto MG, Finkler NJ, Kassis AI, et al. Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-131-labeled monoclonal antibody OC125. Gynecol Oncol. 1992;45(3):265–272.
   PubMed Web of Science ®Google Scholar
• Greiner JW, Guadagni F, Goldstein D, et al. Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells. J Clin Oncol. 1992;10(5):735–746.
   PubMed Web of Science ®Google Scholar
• Freedman RS, Tomasovic B, Templin S, et al. Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy. J Immunol Methods. 1994;167(1–2):145–160.
   PubMed Web of Science ®Google Scholar
• Yamaguchi Y, Satoh Y, Miyahara E, et al. Locoregional immunotherapy of malignant ascites by intraperitoneal administration of OK-432 plus IL-2 in gastric cancer patients. Anticancer Res. 1995;15(5b):2201–2206.
   PubMed Web of Science ®Google Scholar
• Freedman RS, Vadhan-Raj S, Butts C, et al. Pilot study of Flt3 ligand comparing intraperitoneal with subcutaneous routes on hematologic and immunologic responses in patients with peritoneal carcinomatosis and mesotheliomas. Clin Cancer Res off J Am Assoc Cancer Res. 2003;9(14):5228–5237.
   PubMed Web of Science ®Google Scholar
• Urba WJ, Clark JW, Steis RG, et al. Intraperitoneal lymphokine-activated killer cell/interleukin-2 therapy in patients with intra-abdominal cancer: immunologic considerations. J Natl Cancer Inst. 1989;81(8):602–611.
   PubMedGoogle Scholar
• Bast RC Jr., Berek JS, Obrist R, et al. Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum. Cancer Res. 1983;43(3):1395–1401.
   PubMed Web of Science ®Google Scholar
• Berek JS, Hacker NF, Lichtenstein A, et al. Intraperitoneal recombinant alpha-interferon for “salvage” immunotherapy in stage III epithelial ovarian cancer: a gynecologic oncology group study. Cancer Res. 1985;45(9):4447–4453.
   PubMed Web of Science ®Google Scholar
• Chandler C, Bell MM, Chung SK, et al. Intraperitoneal pretargeted radioimmunotherapy for colorectal peritoneal carcinomatosis. Mol Cancer Ther. 2022;21(1):125–137 .
   Web of Science ®Google Scholar
• Hallqvist A, Bergmark K, Bäck T, et al. Intraperitoneal α-emitting radioimmunotherapy with (211) at in relapsed ovarian cancer: long-term follow-up with individual absorbed dose estimations. J Nucl Med. 2019;60(8):1073–1079.
   PubMed Web of Science ®Google Scholar
• Yoshii Y, Matsumoto H, Yoshimoto M, et al. (64)cu-intraperitoneal radioimmunotherapy: a novel approach for adjuvant treatment in a clinically relevant preclinical model of pancreatic cancer. J Nucl Med. 2019;60(10):1437–1443.
   PubMed Web of Science ®Google Scholar
• Rondon A, Schmitt S, Briat A, et al. Pretargeted radioimmunotherapy and SPECT imaging of peritoneal carcinomatosis using bioorthogonal click chemistry: probe selection and first proof-of-concept. Theranostics. 2019;9(22):6706–6718.
   PubMed Web of Science ®Google Scholar
• Meredith RF, Torgue JJ, Rozgaja TA, et al. Safety and outcome measures of first-in-human intraperitoneal α radioimmunotherapy With 212Pb-TCMC-trastuzumab. Am J Clin Oncol. 2018;41(7):716–721.
   PubMed Web of Science ®Google Scholar
• Meredith R, You Z, Alvarez R, et al. Predictors of long-term outcome from intraperitoneal radioimmunotherapy for ovarian cancer. Cancer Biother Radiopharm. 2012;27(1):36–40.
   PubMed Web of Science ®Google Scholar
• Schoffelen R, van der Graaf WT, Sharkey RM, et al. Quantitative immuno-SPECT monitoring of pretargeted radioimmunotherapy with a bispecific antibody in an intraperitoneal nude mouse model of human colon cancer. J Nucl Med. 2012;53(12):1926–1932.
   PubMed Web of Science ®Google Scholar
• Ramanathan R, Choudry H, Jones H, et al. Phase II trial of adjuvant dendritic cell vaccine in combination with celecoxib, interferon-α, and rintatolimod in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastases. Ann Surg Oncol. 2021;28(8):4637–4646.
   PubMed Web of Science ®Google Scholar
• Hong X, Dong T, Yi T, et al. Impact of 5-Fu/oxaliplatin on mouse dendritic cells and synergetic effect with a colon cancer vaccine. Chin J Cancer Res. 2018;30(2):197–208.
   PubMed Web of Science ®Google Scholar
• Furugaki K, Cui L, Kunisawa Y, et al. Intraperitoneal administration of a tumor-associated antigen SART3, CD40L, and GM-CSF gene-loaded polyplex micelle elicits a vaccine effect in mouse tumor models. PloS one. 2014;9(7):e101854.
   PubMed Web of Science ®Google Scholar
• Ang WX, Li Z, Chi Z, et al. Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis. Oncotarget. 2017;8(8):13545–13559.
   PubMed Web of Science ®Google Scholar
• Frøysnes IS, Andersson Y, Larsen SG, et al. Novel treatment with intraperitoneal MOC31PE immunotoxin in colorectal peritoneal metastasis: results from the ImmunoPeCa phase 1 trial. Ann Surg Oncol. 2017;24(7):1916–1922.
   PubMed Web of Science ®Google Scholar
• Liu Z, Ravindranathan R, Kalinski P, et al. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nat Commun. 2017;8(1):14754.
   PubMed Web of Science ®Google Scholar
• He Z, Wang S, Qiao G, et al. Clinical efficacy of intra-cavitary infusions of autologous dendritic cell/cytokine-induced killer cell products for the treatment of refractory malignant pleural effusions and ascites. Am J Transl Res. 2020;12(7):3940–3952.
   PubMed Web of Science ®Google Scholar
• Parente-Pereira AC, Shmeeda H, Whilding LM, et al. Adoptive immunotherapy of epithelial ovarian cancer with Vγ9Vδ2 T cells, potentiated by liposomal alendronic acid. J Immunol. 2014;193(11):5557–5566.
   PubMed Web of Science ®Google Scholar
• Hermanson DL, Bendzick L, Kaufman DS. Mouse xenograft model for intraperitoneal administration of NK cell immunotherapy for ovarian cancer. Methods Mol Biol. 2016;1441:277–284.
   PubMedGoogle Scholar
• Geller MA, Knorr DA, Hermanson DA, et al. Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model. Cytotherapy. 2013;15(10):1297–1306.
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Stein A, Ridwelski K, et al. A phase II study of catumaxomab administered intra- and postoperatively as part of a multimodal approach in primarily resectable gastric cancer. Gastric Cancer. 2015;18(4):833–842.
   PubMed Web of Science ®Google Scholar
• Heiss MM, Ströhlein MA, Bokemeyer C, et al. The role of relative lymphocyte count as a biomarker for the effect of catumaxomab on survival in malignant ascites patients: results from a phase II/III study. Clin Cancer Res off J Am Assoc Cancer Res. 2014;20(12):3348–3357.
   PubMed Web of Science ®Google Scholar
• Goéré D, Gras-Chaput N, Aupérin A, et al. Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab. BMC Cancer. 2014;14(1):148.
   PubMedGoogle Scholar
• Wimberger P, Gilet H, Gonschior AK, et al. Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone. Ann Oncol. 2012;23(8):1979–1985.
   PubMed Web of Science ®Google Scholar
• Ströhlein MA, Lordick F, Rüttinger D, et al. Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial. Onkologie. 2011;34(3):101–108.
   PubMedGoogle Scholar
• Kim C, Kim W, Han Y, et al. Cancer immunotherapy with STING agonist and PD-1 immune checkpoint inhibitor effectively suppresses peritoneal carcinomatosis of colon cancer. Ann Oncol. 2019;30(Suppl 4):iv35–iv.
   Google Scholar
• Miller AM, Lemke-Miltner CD, Blackwell S, et al. Intraperitoneal CMP-001: a novel immunotherapy for treating peritoneal carcinomatosis of gastrointestinal and pancreaticobiliary cancer. Ann Surg Oncol. 2021;28(2):1187–1197.
   PubMed Web of Science ®Google Scholar
• Freedman RS, Kudelka AP, Kavanagh JJ, et al. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma. Clin Cancer Res off J Am Assoc Cancer Res. 2000;6(6):2268–2278.
   PubMed Web of Science ®Google Scholar
• Choudhry H, Helmi N, Abdulaal WH, et al. Prospects of IL-2 in cancer immunotherapy. Biomed Res Int. 2018;2018:9056173.
   PubMed Web of Science ®Google Scholar
• Vlad AM, Budiu RA, Lenzner DE, et al. A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer. Cancer Immunol Immunother. 2010;59(2):293–301.
   PubMed Web of Science ®Google Scholar
• Al-Quteimat OM, Al-Badaineh MA. Intraperitoneal chemotherapy: rationale, applications, and limitations. J Oncol Pharm Pract. 2014;20(5):369–380.
   PubMed Web of Science ®Google Scholar
• Yamaguchi Y, Ohshita A, Kawabuchi Y, et al. Locoregional immunotherapy of malignant ascites from gastric cancer using DTH-oriented doses of the streptococcal preparation OK-432: treatment of Th1 dysfunction in the ascites microenvironment. Int J Oncol. 2004;24(4):959–966.
   PubMed Web of Science ®Google Scholar
• Sartori S, Nielsen I, Tassinari D, et al. Evaluation of a standardized protocol of intracavitary recombinant interferon alpha-2b in the palliative treatment of malignant peritoneal effusions. A prospective pilot study. Oncology. 2001;61(3):192–196.
   PubMed Web of Science ®Google Scholar
• Stewart JS, Hird V, Sullivan M, et al. Intraperitoneal radioimmunotherapy for ovarian cancer. Br J Obstet Gynaecol. 1989;96(5):529–536.
   PubMedGoogle Scholar
• Parker N, Turk MJ, Westrick E, et al. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem. 2005;338(2):284–293.
   PubMed Web of Science ®Google Scholar
• Flies DB, Chen L. The new B7s: playing a pivotal role in tumor immunity. J Immunother. 2007;30(3):251–260.
   PubMed Web of Science ®Google Scholar
• Fossati M, Buzzonetti A, Monego G, et al. Immunological changes in the ascites of cancer patients after intraperitoneal administration of the bispecific antibody catumaxomab (anti-EpCAM×anti-CD3). Gynecol Oncol. 2015;138(2):343–351.
   PubMed Web of Science ®Google Scholar
• Amann M, Brischwein K, Lutterbuese P, et al. Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3. Cancer Res. 2008;68(1):143–151.
   PubMed Web of Science ®Google Scholar
• Went P, Vasei M, Bubendorf L, et al. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer. 2006;94(1):128–135.
   PubMed Web of Science ®Google Scholar
• Zeidler R, Mysliwietz J, Csánady M, et al. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer. 2000;83(2):261–266.
   PubMed Web of Science ®Google Scholar
• Atanackovic D, Reinhard H, Meyer S, et al. The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting. Hum Vaccin Immunother. 2013;9(12):2533–2542.
   PubMed Web of Science ®Google Scholar
• Knödler M, Körfer J, Kunzmann V, et al. Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer. Br J Cancer. 2018;119(3):296–302.
   PubMed Web of Science ®Google Scholar
• Cunliffe TG, Bates EA, Parker AL. Hitting the target but missing the point: recent progress towards adenovirus-based precision virotherapies. Cancers (Basel). 2020;12(11):3327.
   PubMed Web of Science ®Google Scholar
• Alkayyal AA, Tai LH, Kennedy MA, et al. NK-cell recruitment is necessary for eradication of peritoneal carcinomatosis with an IL12-expressing maraba virus cellular vaccine. Cancer Immunol Res. 2017;5(3):211–221.
   PubMed Web of Science ®Google Scholar
• Lauer UM, Schell M, Beil J, et al., Phase I study of oncolytic vaccinia virus GL-ONC1 in patients with peritoneal carcinomatosis. Clin Cancer Res off J Am Assoc Cancer Res. 24(18): 4388–4398. 2018.
   PubMed Web of Science ®Google Scholar
• Bett AJ, Prevec L, Graham FL. Packaging capacity and stability of human adenovirus type 5 vectors. J Virol. 1993;67(10):5911–5921.
   PubMed Web of Science ®Google Scholar
• Waddington SN, McVey JH, Bhella D, et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell. 2008;132(3):397–409.
   PubMed Web of Science ®Google Scholar
• Uusi-Kerttula H, Davies JA, Thompson JM, et al. Ad5(NULL)-A20: a tropism-modified, αvβ6 integrin-selective oncolytic adenovirus for epithelial ovarian cancer therapies. Clin Cancer Res off J Am Assoc Cancer Res. 2018;24(17):4215–4224.
   PubMed Web of Science ®Google Scholar
• Ai YQ, Cai K, Hu JH, et al. The clinical effects of dendritic cell vaccines combined with cytokine-induced killer cells intraperitoneal injected on patients with malignant ascites. Int J Clin Exp Med. 2014;7(11):4272–4281.
   PubMed Web of Science ®Google Scholar
• Chiang CL, Kandalaft LE, Tanyi J, et al. A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Clin Cancer Res off J Am Assoc Cancer Res. 2013;19(17):4801–4815.
   PubMed Web of Science ®Google Scholar
• Adams SF, Grimm AJ, Chiang CL, et al. Rapid tumor vaccine using Toll-like receptor-activated ovarian cancer ascites monocytes. J Immunother Cancer. 2020;8(2):e000875.
   PubMed Web of Science ®Google Scholar
• Koneru M, O’Cearbhaill R, Pendharkar S, et al. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer. J Transl Med. 2015;13(1):102.
   PubMedGoogle Scholar
• Thadi A, Khalili M, Morano WF, et al. Early investigations and recent advances in intraperitoneal immunotherapy for peritoneal metastasis. Vaccines (Basel). 2018;6(3):54.
   Web of Science ®Google Scholar
• Katz SC, Point GR, Cunetta M, et al., Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery. Cancer Gene Ther. 23(5): 142–148. 2016.
   PubMed Web of Science ®Google Scholar
• Koneru M, Purdon TJ, Spriggs D, et al. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology. 2015;4(3):e994446.
   PubMed Web of Science ®Google Scholar
• Hege KM, Bergsland EK, Fisher GA, et al. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. J Immunother Cancer. 2017;5(1):22.
   PubMed Web of Science ®Google Scholar
• Han Y, Liu C, Li G, et al. Antitumor effects and persistence of a novel HER2 CAR T cells directed to gastric cancer in preclinical models. Am J Cancer Res. 2018;8(1):106–119.
   PubMed Web of Science ®Google Scholar
• Murad JP, Kozlowska AK, Lee HJ, et al. Effective targeting of TAG72(+) peritoneal ovarian tumors via regional delivery of CAR-engineered T cells. Front Immunol. 2018;9:2268.
   PubMed Web of Science ®Google Scholar
• Li Z, Chi Z, Ang WX, et al. Experimental treatment of colorectal cancer in mice with human T cells electroporated with NKG2D RNA CAR. Immunotherapy. 2020;12(10):733–748.
   PubMed Web of Science ®Google Scholar
• Wang C, Steinmetz NF. A combination of cowpea mosaic virus and immune checkpoint therapy synergistically improves therapeutic efficacy in three tumor models. Adv Funct Mater. 2020;30(27):2002299.
   PubMed Web of Science ®Google Scholar
• Si X, Ji G, Ma S, et al. Biodegradable implants combined with immunogenic chemotherapy and immune checkpoint therapy for peritoneal metastatic carcinoma postoperative treatment. ACS Biomater Sci Eng. 2020;6(9):1618–1619.
   Web of Science ®Google Scholar
• Ma Z, Li W, Yoshiya S, et al. Augmentation of immune checkpoint cancer immunotherapy with IL18. Clin Cancer Res off J Am Assoc Cancer Res. 2016;22(12):2969–2980.
   PubMed Web of Science ®Google Scholar